Results from a major international study raise hopes for one of the biggest breakthroughs in pancreatic cancer in decades.
The new drug daraxonrasib has been shown to double survival in patients with metastatic disease while causing fewer side effects than traditional chemotherapy.
Results from a study involving approximately 500 patients with metastatic pancreatic cancer were recently presented at the American Society of Clinical Oncology (ASCO) conference. Patients treated with the new daraxonrasib tablet lived an average of 13.2 months, compared to 6.6–6.7 months for patients receiving standard chemotherapy treatment.
Potential paradigm shift
Several leading cancer experts describe the results as a breakthrough and a potential paradigm shift for a form of cancer where treatment options have long been very limited. More than half of patients are not diagnosed until the disease has already spread, and survival rates have long been very low.
Daraxonrasib targets the KRAS protein, which drives growth in most cases of pancreatic cancer. Over 90 percent of patients with the most common form of the disease have a KRAS mutation. By blocking this protein, the drug can slow tumor growth regardless of which type of KRAS variant the patient has.
Researchers describe the ability to effectively target KRAS as the “holy grail” of cancer research. The study now shows that this is not only possible but can also yield significant clinical benefits for patients.
Patient organizations welcome the results. For many patients, a few extra months mean not only longer survival but also valuable time spent with family and loved ones.
The next major challenge will be ensuring that this type of medication can be made available to patients quickly. At the same time, these successes raise hopes that similar treatments may also be effective for other types of cancer, such as lung and colorectal cancer, where KRAS mutations also play an important role.
When will Daraxonrasib become available to Swedish patients?
Daraxonrasib is still an investigational drug and has not yet received full marketing approval. Following the very strong Phase 3 results, Revolution Medicines has announced that it intends to submit an application for approval to the FDA in the U.S.
Possible timeline
U.S.: The FDA has already granted the drug several fast-track designations, including Breakthrough Therapy status and priority review. Several analysts therefore believe that U.S. approval could come in 2026, if the agency deems the data sufficiently strong.
EU: Following potential FDA approval, a separate application must typically be submitted to the European Medicines Agency (EMA). European approval usually follows 6–18 months later, although the process can be expedited for drugs with a high unmet medical need.
An assessment
If the current results hold up and no unexpected safety issues arise, a realistic scenario is:
U.S.: available in 2026.
Sweden: no earlier than 2027, but this depends on how quickly the EMA, TLV, and the regions process the application.
For those affected by PALEMA, this is likely the most promising drug news in pancreatic cancer in many years, as the survival benefit in the study is significantly greater than what is normally seen in late-stage studies for advanced disease.
Video
Watch the video “RASolute-302 with Daraxonrasib – Game Changer at ASCO 2026 in Pancreatic Cancer” from the YouTube channel “@oncologybrothers“
